West Pharmaceutical Services, Inc. — 2020 Form 10-K Summary
Business Context and Reporting Period
West Pharmaceutical Services, Inc. designs and manufactures containment, packaging, delivery systems and contract-manufactured devices for injectable drugs and healthcare products. Operations are reported through Proprietary Products and Contract-Manufactured Products. The filing covers the fiscal year ended December 31, 2020, with comparative information for 2019 and 2018. The company reported substantial international exposure, with 54.6% of 2020 sales generated outside the United States.
Key Financial Metrics
| Metric | 2020 | 2019 | Change |
|---|---|---|---|
| Net sales | $2,146.9 million | $1,839.9 million | +16.7% |
| Gross profit | $767.8 million | $605.7 million | +26.8% |
| Gross margin | 35.8% | 32.9% | +2.9 points |
| Operating profit | $406.9 million | $296.6 million | +37.2% |
| Operating margin | 19.0% | 16.1% | +2.9 points |
| Adjusted operating profit | $417.0 million | $296.4 million | +40.7% |
| Net income | $346.2 million | $241.7 million | +43.3% |
| Diluted EPS | $4.57 | $3.21 | +42.4% |
| Operating cash flow | $472.5 million | $367.2 million | +28.7% |
| Capital expenditures | $174.4 million | $126.4 million | +38.0% |
Proprietary Products sales increased 17.9% to $1,648.6 million, while Contract-Manufactured Products sales increased 12.9% to $498.6 million. Approximately $99 million of Proprietary Products sales reflected COVID-19-related activity, including demand associated with vaccines, antiviral treatments and treatment of COVID-19 symptoms.
At December 31, 2020, cash and cash equivalents were $615.5 million, working capital was $870.3 million, total debt was $255.2 million and equity was $1,854.5 million. The company had no borrowings under its $300 million revolving credit facility and reported $297.5 million of available capacity, including outstanding letters of credit. Debt maturities include $134.0 million in 2024 and $73.0 million thereafter.
Net cash used in investing activities was $179.5 million, primarily reflecting capital expenditures. Net cash used in financing activities was $137.1 million, including $115.5 million of share repurchases and $48.1 million of dividend payments. The 2020 dividend declared was $0.66 per share, and the fourth-quarter dividend was increased to $0.17 per share.
Material Changes Versus the Prior Comparable Period
- Sales growth accelerated materially, led by high-value components, delivery platforms and healthcare-related injection and diagnostic devices.
- Gross margin expanded from 32.9% to 35.8%, supported by favorable product mix, production efficiencies and price increases, partially offset by higher compensation and COVID-19 costs.
- Operating margin increased to 19.0%; adjusted operating margin increased to 19.4% from 16.1%.
- SG&A increased 10.7% to $302.0 million, primarily because of higher stock-based compensation, incentive compensation and consulting costs. SG&A as a percentage of sales declined to 14.1% from 14.8%.
- Research and development spending increased 20.6% to $46.9 million, focused on self-injection systems, transfer devices, elastomeric packaging and formulation development.
- Operating cash flow increased by $105.3 million, while inventory increased to $321.3 million from $235.7 million to support customer demand.
- Debt declined modestly by $2.1 million as the company repaid part of its Term Loan. Cash increased by $176.4 million during the year.
- West increased its ownership interest in Daikyo to 49% in late 2019; equity in affiliated-company earnings rose to $17.4 million from $8.9 million.
Guidance, Outlook, Risks and Unusual Items
The filing does not provide a clear numerical 2021 revenue or earnings guidance figure. Management stated that cash on hand, operating cash flow and revolving-credit availability should satisfy foreseeable liquidity needs, and expected continued compliance with debt covenants throughout 2021.
- COVID-19 could disrupt employees, suppliers, transportation, manufacturing and customer demand. Manufacturing operations generally continued during 2020, with enhanced safety measures and increased production at certain sites.
- A restructuring plan approved in July 2020 is expected to require total charges of approximately $15 million to $17 million. The company recorded $4.6 million in 2020 and expects annualized savings of $3.5 million to $4.5 million when completed.
- Other 2020 unusual items included $7.7 million of fixed-asset impairments and disposal-related charges, $3.7 million of pension settlement charges, $2.5 million of cost-investment impairment and $0.6 million of acquisition-related intangible amortization.
- The effective tax rate declined to 18.1% from 20.2%, aided by a $20.8 million tax benefit from stock-based compensation and lower taxes on international operations.
- The company continues to face risks from single-source raw materials, manufacturing concentration, foreign currency movements, commodity prices, regulatory approvals, product defects or recalls, cybersecurity, pricing pressure and pharmaceutical-industry consolidation.
- The Vial2Bag product recall initiated in 2019 remained a relevant unusual item. West received FDA market clearance for the Vial2Bag Advanced 20mm Admixture Device on October 21, 2020 and was working to return the products to market.
- LIBOR-based variable-rate debt and a cross-currency swap expose the company to benchmark-transition and interest-rate risk.
- Contractual obligations totaled $497.1 million, including $118.4 million of purchase obligations, $255.8 million of debt, $85.2 million of operating lease obligations and $30.3 million of debt-related interest obligations.
Most Important Facts to Verify
- Whether COVID-19-related demand, including approximately $99 million of 2020 activity, persists or normalizes.
- The timing and total cost of the restructuring plan and whether projected annual savings of $3.5 million to $4.5 million are achieved.
- Capacity utilization, capital-spending returns and the effect of increased inventory on future cash conversion.
- Debt repayment schedules, variable-rate exposure, LIBOR replacement provisions and covenant compliance.
- Progress and financial impact of the Vial2Bag product relaunch following FDA clearance.
- The sustainability of margin expansion, favorable product mix and tax benefits from stock-based compensation.
- Foreign-currency effects given the company’s international sales and operations.
- Potential obligations from $10.4 million of unrecognized tax benefits, pension underfunding of $40.8 million and SmartDose contingent consideration, with an estimated probable five-year range of zero to $4.3 million.
- Reliance on key customers and suppliers: the ten largest customers represented 42.0% of sales, although no individual customer exceeded 10%.